Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Verigy
So what: Last November, Verigy agreed to purchase rival LTX-Credence
Now what: Today, Verigy's board announced the Advantest offer is "superior" and it will withdraw its recommendation in favor of acquiring LTX-Credence. This sets the stage for a legal battle, with a likely outcome that Verigy can get out of the agreement with LTX-Credence (though there may be a fee involved to quit the deal). This gives Verigy good odds of being acquired by Advantest for $15 per share, an 18% premium to Friday's close.
Interested in more info on Verigy? Add it to your watchlist by clicking here.